You are here

Article Text

Article menu
Download PDFPDF
DTB select
Safety update: dupilumab and ocular adverse reactions

Abstract

Overview of: Medicines and Healthcare products Regulatory Agency. Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management. Drug Safety Update 2022;16(4): 1.

  • Health Care Quality, Access, and Evaluation
  • Drug-Related Side Effects and Adverse Reactions

https://doi.org/10.1136/dtb.2022.000073

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.